Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Recursion Pharmaceuticals, Inc. on June 17, 2026. The filing details the voting results for director elections, executive compensation approval, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Director Election): Stockholders elected Najat Khan, Ph.D., and Franziska Michor, Ph.D., as Class II directors to serve until the 2029 annual meeting.
- Najat Khan: 210,437,751 For; 27,907,256 Withheld; 126,675,762 Broker Non-Votes.
- Franziska Michor: 208,124,737 For; 30,220,270 Withheld; 126,675,762 Broker Non-Votes.
- Proposal 2 (Executive Compensation): The advisory resolution to approve executive compensation was approved.
- Votes: 206,171,008 For; 30,893,147 Against; 1,280,852 Abstain; 126,675,762 Broker Non-Votes.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026.
- Votes: 361,743,500 For; 2,148,771 Against; 1,128,498 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the definitive Proxy Statement filed on April 30, 2026, for detailed biographies of the elected directors and executive compensation specifics.
- Note the significant number of Broker Non-Votes (126,675,762) on the director election and compensation proposals, indicating shares held by brokers that were not voted on these matters.
- Confirm the tenure of the newly elected directors, which extends through the 2029 annual meeting.
- Review the upcoming 2026 annual report for financial performance data, as this 8-K contains no financial metrics.